ReviewNature reviews. Clinical oncology2013
Minimal residual disease in acute myeloid leukaemia.
Review in Nature reviews. Clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 2 syntheses or guidelines pooled it, 179 citations in OpenAlex.
- Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.JAMA oncology · 2020Pooled it
- Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.Haematologica · 2017Pooled it
- Trial
- Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes.Haematologica · 2017Trial
- A multigene array for measurable residual disease detection in AML patients undergoing SCT.Bone marrow transplantation · 2015Trial
- Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation.Bone marrow transplantation · 2015Trial
- Efficacy of Tucidinostat Pre-emptive Therapy for Peripheral T-cell Lymphoma after Allogeneic Stem Cell Transplantation.Internal medicine (Tokyo, Japan) · 2026Article
- Immune monitoring for relapse of acute myeloid leukemia after allogeneic stem cell transplantation in clinical laboratories.Frontiers in immunology · 2026Review
- Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia.Nature biomedical engineering · 2025Article
- Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: a narrative review.Translational lung cancer research · 2025Review
- Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.Bone marrow transplantation · 2025Article
- Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice.Bone marrow transplantation · 2025Review
- Gene expression profiling and pathway analysis in acute myeloid leukaemia-normal karyotype patients.PloS one · 2025Article
- Acute Myeloid Leukemia-Use of Measurable Residual Disease to Improve Outcomes.Advances in experimental medicine and biology · 2025Review
- Revumenib (SNDX-5613): a promising menin inhibitor for the management of relapsed and refractory acute myeloid leukaemia (AML).Annals of medicine and surgery (2012) · 2024Article
- Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.Transplantation and cellular therapy · 2024Review
- Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.Haematologica · 2024Article
- Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia.EJHaem · 2024Article
- Article
- Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.Molecular diagnosis & therapy · 2023Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Technological advances in the laboratory have led to substantial improvements in clinical decision making through the introduction of pretreatment prognostic risk stratification factors in acute myeloid leukaemia (AML). Unfortunately, similar progress has not been made in treatment response criteria, with the definition of 'complete remission' in AML largely unchanged for over half a century. Several clinical trials have demonstrated that high-sensitivity measurements of residual disease burden during or after treatment can be performed, that results are predictive for clinical outcome and can be used to improve outcomes by guiding additional therapeutic intervention to patients in clinical complete remission, but at increased relapse risk. We review these recent trials, the characteristics and challenges of the modalities currently used to detect minimal residual disease (MRD), and outline opportunities to both refine detection and improve clinical use of MRD measurements. MRD measurement is already the standard of care in other myeloid malignancies, such as chronic myelogenous leukaemia and acute promyelocytic leukaemia (APL). It is our belief that response criteria for non-APL AML should be updated to include assessment for molecular complete remission and recommendations for post-consolidation surveillance should include regular monitoring for molecular relapse as standard of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.